Publication | Closed Access
A Robust ROS Generation Strategy for Enhanced Chemodynamic/Photodynamic Therapy via H<sub>2</sub>O<sub>2</sub>/O<sub>2</sub> Self‐Supply and Ca<sup>2+</sup> Overloading
139
Citations
32
References
2021
Year
NanotherapeuticsReactive Oxygen SpeciesRedox BiologyOxidative StressNanomedicineEnhanced Chemodynamic/photodynamic TherapyTherapeutic NanomaterialsCancer Cell BiologyChemodynamic TherapyBioimagingPhotosensitizersRadiation OncologyBiophysicsHealth SciencesPhotochemistryPhotodynamic TherapyMechanistic PhotochemistryTumor TargetingBiophotonicsTumor MicroenvironmentBiomolecular EngineeringSmart Polyethylene GlycolMedicine
Abstract The efficacy of cancer therapy with reactive oxygen species (ROS) as the main therapeutic medium suffers from a deficiency of oxy‐substrates, for example, insufficient endogenous hydrogen peroxide (H 2 O 2 ) in chemodynamic therapy (CDT) and inherent hypoxia in photodynamic therapy (PDT). Herein, a smart polyethylene glycol (PEG)‐ylated nanosystem CaO 2 @ZIF‐Fe/Ce6@PEG (abbreviation as CaZFCP) is constructed to achieve H 2 O 2 /O 2 self‐supply and Ca 2+ overloading in tumor cells simultaneously for enhanced CDT/PDT. Under the weakly acidic tumor microenvironment, the activity components inside CaZFCP, that is, CaO 2 nanoparticles, Fe 2+ , and photosensitizer Chlorin e6 (Ce6) are released by the degradation of zeolitic imidazole framework‐90 (ZIF‐90). Thereinto, CaO 2 nanoparticles are further decomposed to generate H 2 O 2 and O 2 , which alleviates both the insufficient endogenous H 2 O 2 and hypoxia in tumor area, thus enhancing the efficiency of CDT and PDT by producing more hydroxyl radicals and singlet oxygen. Furthermore, Ca 2+ overloading induced by the decomposition of CaO 2 is available for amplifying intracellular oxidative stress, resulting in mitochondrial dysfunction, which further improves the efficacy of combined CDT/PDT. In vitro and in vivo experimental results confirm excellent tumor inhibition effect, which also provides a facile paradigm in ROS‐involved cancer therapies.
| Year | Citations | |
|---|---|---|
Page 1
Page 1